These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17192906)

  • 1. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.
    Berenguer M; Royuela A; Zamora J
    Liver Transpl; 2007 Jan; 13(1):21-9. PubMed ID: 17192906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases.
    Kulbat A; Richter K; Stefura T; Kołodziej-Rzepa M; Kisielewski M; Wojewoda T; Wysocki WM
    Curr Oncol; 2023 Jun; 30(6):5727-5737. PubMed ID: 37366913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.
    Locke JE; Singer AL
    Hepat Med; 2011 May; 3():53-62. PubMed ID: 24367221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitors in the management of recurrent miscarriage and recurrent implantation failure: Systematic review and meta-analysis.
    Cavalcante MB; Tavares ACM; Rocha CA; de Souza GF; Lima EM; Simões JML; de Souza LC; Martins MYM; de Araújo NO; Barini R
    J Reprod Immunol; 2023 Dec; 160():104157. PubMed ID: 37813069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.
    Peláez-Jaramillo MJ; Cárdenas-Mojica AA; Gaete PV; Mendivil CO
    Diabetes Ther; 2018 Apr; 9(2):521-543. PubMed ID: 29411291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis.
    Rabindranath M; Zaya R; Prayitno K; Orchanian-Cheff A; Patel K; Jaeckel E; Bhat M
    Transplant Direct; 2023 Nov; 9(11):e1547. PubMed ID: 37854023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation.
    Engel B; Falk Villesen I; Fisker Nielsen MJ; Karsdal M; Taubert R; Jaeckel E; Leeming DJ
    Sci Rep; 2023 Apr; 13(1):6103. PubMed ID: 37055472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C viral infection after liver transplantation.
    Verna EC; Brown RS
    Clin Liver Dis (Hoboken); 2012 Jul; 1(3):73-76. PubMed ID: 31186853
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus: Management of recurrent disease.
    Verna EC
    Clin Liver Dis (Hoboken); 2013 Aug; 2(4):177-180. PubMed ID: 30992857
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.
    Albekairy AM; Abdel-Razaq WS; Alkatheri AM; Debasi TMA; Otaibi NEA; Qandil AM
    Int J Health Sci (Qassim); 2018; 12(4):78-87. PubMed ID: 30022908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.
    Kim JM; Lee KW; Song GW; Jung BH; Lee HW; Yi NJ; Kwon CD; Hwang S; Suh KS; Joh JW; Lee SK; Lee SG
    Clin Mol Hepatol; 2016 Sep; 22(3):366-371. PubMed ID: 27729628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of liver transplantation in human immunodeficiency virus positive patients.
    Joshi D; Agarwal K
    World J Gastroenterol; 2015 Nov; 21(43):12311-21. PubMed ID: 26604639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatobiliary quiz-8 (2013).
    Agrawal S; Dhiman RK
    J Clin Exp Hepatol; 2013 Dec; 3(4):357-61. PubMed ID: 25755526
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of immunosuppression in liver transplantation.
    Choudhary NS; Saigal S; Shukla R; Kotecha H; Saraf N; Soin AS
    J Clin Exp Hepatol; 2013 Jun; 3(2):150-8. PubMed ID: 25755489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of recurrent hepatitis C virus after liver transplantation.
    Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
    World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
    Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
    World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
    Liu Z; Chen Y; Tao R; Xv J; Meng J; Yong X
    PLoS One; 2014; 9(9):e107057. PubMed ID: 25198195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
    Grassi A; Ballardini G
    World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent hepatitis C after liver transplant.
    deLemos AS; Schmeltzer PA; Russo MW
    World J Gastroenterol; 2014 Aug; 20(31):10668-81. PubMed ID: 25152571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.
    Fernández-Yunquera A; Ripoll C; Bañares R; Puerto M; Rincón D; Yepes I; Catalina V; Salcedo M
    World J Transplant; 2014 Jun; 4(2):133-40. PubMed ID: 25032102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.